Mumbai (Maharashtra) [India], January 17 (ANI/PRNewswire): Glenmark Pharmaceuticals Inc., USA (Glenmark) has received tentative approval by the United States FoodDrug Administration (U.S. FDA) for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single-Dose Pre-Filled Syringe, the generic version of Lexiscanreg;1 Injection, 0.4 mg/5 mL (0.08 mg/mL), of Astellas US, Inc.
According to IQVIATM sales data for the 12 month period ending November 2021, the Lexiscanreg;Injection, 0.4 mg/5 mL (0.08 mg/mL) market2 achieved annual sales of approximately $659.9 million.Glenmark's current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 47 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
References:1All brand names and trademarks are the property of their respective owners.
2Market includes brand and all available therapeutic equivalentsIQVIATM National Sales Perspectives: RetailNon-Retail, November 2021Glenmark Pharmaceuticals Limited (Glenmark) is a global research-led pharmaceutical company with presence across generics, specialty and OTC businesses and with operations in over 80 countries. Glenmark's key therapeutic areas of focus are respiratory, dermatology and oncology. It ranks among the world's top 50 Generics and Biosimilar companies (Top 50 Company Rankings, 2020, from Informa's Generics Bulletin).
The company has been listed on the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for the fourth consecutive year in a row. DJSI is one of the world's most respected and widely accepted sustainability benchmarks globally with only the top ranked companies in terms of Corporate Sustainability within each industry being featured in the index. For more information, visitFor more information, please contact:Udaykumar MurthyDeputy General Manager, Corporate Communications91firstname.lastname@example.orgThis story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)